Vanda Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Vanda Pharmaceuticals's earnings have been declining at an average annual rate of -37.5%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 2.4% per year. Vanda Pharmaceuticals's return on equity is 0.5%, and it has net margins of 1.3%.
Key information
-37.5%
Earnings growth rate
-38.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 2.4% |
Return on equity | 0.5% |
Net Margin | 1.3% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vanda Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 193 | 3 | 113 | 77 |
30 Sep 23 | 212 | 12 | 122 | 71 |
30 Jun 23 | 238 | 15 | 127 | 79 |
31 Mar 23 | 257 | 16 | 132 | 84 |
31 Dec 22 | 254 | 6 | 136 | 86 |
30 Sep 22 | 258 | 6 | 137 | 87 |
30 Jun 22 | 263 | 11 | 140 | 81 |
31 Mar 22 | 266 | 18 | 135 | 80 |
31 Dec 21 | 269 | 33 | 124 | 75 |
30 Sep 21 | 268 | 34 | 126 | 71 |
30 Jun 21 | 259 | 32 | 128 | 64 |
31 Mar 21 | 253 | 32 | 133 | 56 |
31 Dec 20 | 248 | 23 | 141 | 56 |
30 Sep 20 | 241 | 19 | 142 | 54 |
30 Jun 20 | 241 | 114 | 138 | 53 |
31 Mar 20 | 237 | 117 | 136 | 51 |
31 Dec 19 | 227 | 116 | 130 | 49 |
30 Sep 19 | 219 | 122 | 118 | 48 |
30 Jun 19 | 209 | 28 | 113 | 49 |
31 Mar 19 | 197 | 22 | 110 | 47 |
31 Dec 18 | 193 | 25 | 106 | 44 |
30 Sep 18 | 184 | 13 | 112 | 41 |
30 Jun 18 | 177 | 1 | 117 | 40 |
31 Mar 18 | 171 | -5 | 120 | 37 |
31 Dec 17 | 165 | -16 | 124 | 39 |
30 Sep 17 | 159 | -14 | 117 | 36 |
30 Jun 17 | 156 | -10 | 107 | 33 |
31 Mar 17 | 150 | -13 | 101 | 32 |
31 Dec 16 | 146 | -18 | 100 | 29 |
30 Sep 16 | 140 | -32 | 105 | 30 |
30 Jun 16 | 129 | -41 | 101 | 33 |
31 Mar 16 | 121 | -42 | 95 | 32 |
31 Dec 15 | 110 | -40 | 85 | 29 |
30 Sep 15 | 93 | 45 | 73 | 25 |
30 Jun 15 | 80 | 53 | 66 | 19 |
31 Mar 15 | 63 | 36 | 76 | 16 |
31 Dec 14 | 50 | 20 | 85 | 19 |
30 Sep 14 | 44 | -57 | 77 | 21 |
30 Jun 14 | 37 | -61 | 72 | 25 |
31 Mar 14 | 35 | -43 | 49 | 28 |
31 Dec 13 | 34 | -21 | 25 | 29 |
30 Sep 13 | 33 | -20 | 18 | 33 |
30 Jun 13 | 33 | -20 | 15 | 35 |
Quality Earnings: VM4 has a high level of non-cash earnings.
Growing Profit Margin: VM4's current net profit margins (1.3%) are lower than last year (2.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VM4's earnings have declined by 37.5% per year over the past 5 years.
Accelerating Growth: VM4's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VM4 had negative earnings growth (-60%) over the past year, making it difficult to compare to the Biotechs industry average (-2.3%).
Return on Equity
High ROE: VM4's Return on Equity (0.5%) is considered low.